JP2004075695A - 眼の発達の治療及び制御 - Google Patents
眼の発達の治療及び制御 Download PDFInfo
- Publication number
- JP2004075695A JP2004075695A JP2003397487A JP2003397487A JP2004075695A JP 2004075695 A JP2004075695 A JP 2004075695A JP 2003397487 A JP2003397487 A JP 2003397487A JP 2003397487 A JP2003397487 A JP 2003397487A JP 2004075695 A JP2004075695 A JP 2004075695A
- Authority
- JP
- Japan
- Prior art keywords
- eye
- pirenzepine
- receptor
- smooth muscle
- muscarinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
成熟期動物の眼の異常な出生後軸生長を、動物の出生後の成熟期間に阻止するための薬剤を提供すること。
【解決手段】
成熟期動物の眼の異常な出生後軸生長を、動物の出生後の成熟期間に阻止するための薬剤であって、治療上有効な量の比較的脳、神経組織及び/又は神経節の細胞におけるM1 コリン作動性レセプターをブロックする事に選択的であるが、眼の前方における平滑筋の細胞におけるM3 コリン作動性レセプターをブロックする事にはもっと弱い選択性を有し、M3 平滑筋レセプターに対するよりも少なくとも5倍大きいM1 レセプターに対する親和性を有する、かつ、前記眼の異常な出生後軸生長を阻害するのに有効なムスカリン薬理学的アンタゴニストを含む(但し、ピレンゼピン、テレンゼピン及び3環化合物であるムスカリン薬理学的アンタゴニストを除く)薬剤を提供する。
Description
視神経に伝達する。
プターのアンタゴニスト結合特性を測定するための当業者に知られた技術の詳細な記述は、Buckley ら、Molecular Pharmacology, 35: 469-476 (1989)を参照されたい。同様に、M1 感受性を測定するための機能的研究を達成する多くの方法がある。例えば、1つの現在普及している方法は、M1 感受性のテンジクネズミの精管を用いるものである。初めに、それを、その張力が測定出来るように固定し、そして、M1アゴニストMcNeil A343等の既知の刺激剤を与えて、予想可能な量で張力を変化させる。この条件下で、アゴニストの予想される効果を先ず注意してプロットし、次いで、1種以上のアンタゴニストがこのアゴニストの効果をブロックする程度を測定する。この種の特定の実験において、ピレンゼピンは強いブロック効果を有し、従って、M1 アンタゴニストの性質を証明できるということを示した。
目すべきである。殆どの患者の全身使用において、副作用は最小であり、十分許容性があることが報告されている。
Claims (1)
- 成熟期動物の眼の異常な出生後軸生長を、動物の出生後の成熟期間に阻止するための薬剤であって、治療上有効な量の比較的脳、神経組織及び/又は神経節の細胞におけるM1 コリン作動性レセプターをブロックする事に選択的であるが、眼の前方における平滑筋の細胞におけるM3 コリン作動性レセプターをブロックする事にはもっと弱い選択性を有し、M3 平滑筋レセプターに対するよりも少なくとも5倍大きいM1 レセプターに対する親和性を有する、かつ、前記眼の異常な出生後軸生長を阻害するのに有効なムスカリン薬理学的アンタゴニストを含む(但し、ピレンゼピン、テレンゼピン及び3環化合物であるムスカリン薬理学的アンタゴニストを除く)薬剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36929389A | 1989-06-21 | 1989-06-21 | |
US07/522,241 US5122522A (en) | 1989-06-21 | 1990-05-11 | Treatment and control of ocular development |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000210057A Division JP2001081046A (ja) | 1989-06-21 | 2000-07-11 | 眼の発達の治療及び制御 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2004075695A true JP2004075695A (ja) | 2004-03-11 |
Family
ID=27004525
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51011290A Expired - Fee Related JP3165436B2 (ja) | 1989-06-21 | 1990-06-14 | 眼の発達の治療及び制御 |
JP2000039526A Expired - Fee Related JP3461778B2 (ja) | 1989-06-21 | 2000-02-17 | 眼の発達の治療及び制御 |
JP2000210057A Pending JP2001081046A (ja) | 1989-06-21 | 2000-07-11 | 眼の発達の治療及び制御 |
JP2003397487A Pending JP2004075695A (ja) | 1989-06-21 | 2003-11-27 | 眼の発達の治療及び制御 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51011290A Expired - Fee Related JP3165436B2 (ja) | 1989-06-21 | 1990-06-14 | 眼の発達の治療及び制御 |
JP2000039526A Expired - Fee Related JP3461778B2 (ja) | 1989-06-21 | 2000-02-17 | 眼の発達の治療及び制御 |
JP2000210057A Pending JP2001081046A (ja) | 1989-06-21 | 2000-07-11 | 眼の発達の治療及び制御 |
Country Status (10)
Country | Link |
---|---|
US (2) | US5356892A (ja) |
EP (1) | EP0478694B1 (ja) |
JP (4) | JP3165436B2 (ja) |
AT (3) | ATE203666T1 (ja) |
CA (1) | CA2058768C (ja) |
DE (3) | DE69029734T2 (ja) |
DK (1) | DK0737475T3 (ja) |
ES (2) | ES2159661T3 (ja) |
HK (1) | HK1007681A1 (ja) |
WO (1) | WO1990015604A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1336490C (en) * | 1988-06-03 | 1995-08-01 | Paul Michael Iuvone | Pharmacological treatment of ocular development |
ATE203666T1 (de) * | 1989-06-21 | 2001-08-15 | Univ Pennsylvania | Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung |
WO1993013777A1 (en) * | 1992-01-21 | 1993-07-22 | Merck & Co., Inc. | Method of using m1-selective antimuscarinic pyridobenzodiazepinones in axial myopia therapy |
US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
US5756508A (en) * | 1995-10-31 | 1998-05-26 | Merck & Co., Inc. | Muscarine antagonists |
CA2276287C (en) * | 1997-01-06 | 2007-10-30 | Klaus Trier Aps | Screening method for compounds active in treating myopia and hypermetropia |
US6291466B1 (en) | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
KR20020081260A (ko) * | 2000-01-18 | 2002-10-26 | 밸리 포지 파마슈티컬즈, 인크. | 안구 성장 및 니코틴 길항제 |
NZ529615A (en) * | 2001-05-25 | 2005-07-29 | Valley Forge Pharmaceuticals | Pirenzepine ophthalmic gel |
ITUB20160876A1 (it) | 2016-02-19 | 2017-08-19 | Dambrosio Enzo Maria | Combinazione di un agente antiallergico con un antagonista muscarinico e/o un agonista dopaminergico per l'uso in prevenzione/ arresto di miopia assiale nell’uomo |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU188852B (en) * | 1983-03-16 | 1986-05-28 | Richter Gedeon Vegyeszeti Gyar Rt,Hu | Process for producing thiazolidine derivatives active against gastric ulcer and intestinal ulcer |
US4865599A (en) * | 1986-08-18 | 1989-09-12 | Houston Biotechnology, Inc. | Ophthalmic compositions for treating nerve degeneration |
CA1336490C (en) * | 1988-06-03 | 1995-08-01 | Paul Michael Iuvone | Pharmacological treatment of ocular development |
US5360801A (en) * | 1989-06-21 | 1994-11-01 | The Trustees Of The University Of Pennsylvania | Pharmacological stimulation of eye growth |
US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
ATE203666T1 (de) * | 1989-06-21 | 2001-08-15 | Univ Pennsylvania | Verwendung eines muskarinantagonists zur herstellung eines medikaments für die behandlung und regulierung der augenentwicklung |
US5055302A (en) * | 1990-02-22 | 1991-10-08 | Trustees Of The University Of Pennsylvania | Neuropeptide control of ocular growth |
US5385939A (en) * | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
-
1990
- 1990-06-14 AT AT96108497T patent/ATE203666T1/de not_active IP Right Cessation
- 1990-06-14 EP EP90911118A patent/EP0478694B1/en not_active Expired - Lifetime
- 1990-06-14 DE DE69029734T patent/DE69029734T2/de not_active Expired - Fee Related
- 1990-06-14 ES ES96108497T patent/ES2159661T3/es not_active Expired - Lifetime
- 1990-06-14 WO PCT/US1990/003444 patent/WO1990015604A1/en active IP Right Grant
- 1990-06-14 DE DE69033246T patent/DE69033246T2/de not_active Expired - Fee Related
- 1990-06-14 AT AT94112616T patent/ATE183085T1/de not_active IP Right Cessation
- 1990-06-14 DK DK96108497T patent/DK0737475T3/da active
- 1990-06-14 ES ES94112616T patent/ES2136686T3/es not_active Expired - Lifetime
- 1990-06-14 JP JP51011290A patent/JP3165436B2/ja not_active Expired - Fee Related
- 1990-06-14 AT AT90911118T patent/ATE147626T1/de not_active IP Right Cessation
- 1990-06-14 DE DE69033775T patent/DE69033775T2/de not_active Expired - Fee Related
- 1990-06-14 CA CA002058768A patent/CA2058768C/en not_active Expired - Fee Related
-
1992
- 1992-03-24 US US07/856,626 patent/US5356892A/en not_active Expired - Lifetime
-
1994
- 1994-06-29 US US08/268,035 patent/US5637604A/en not_active Expired - Fee Related
-
1998
- 1998-06-26 HK HK98106920A patent/HK1007681A1/xx not_active IP Right Cessation
-
2000
- 2000-02-17 JP JP2000039526A patent/JP3461778B2/ja not_active Expired - Fee Related
- 2000-07-11 JP JP2000210057A patent/JP2001081046A/ja active Pending
-
2003
- 2003-11-27 JP JP2003397487A patent/JP2004075695A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2058768C (en) | 2004-08-03 |
JP2000204049A (ja) | 2000-07-25 |
ATE203666T1 (de) | 2001-08-15 |
CA2058768A1 (en) | 1990-12-22 |
DE69033246T2 (de) | 1999-12-02 |
JP3461778B2 (ja) | 2003-10-27 |
JPH05500502A (ja) | 1993-02-04 |
US5637604A (en) | 1997-06-10 |
DE69029734T2 (de) | 1997-05-28 |
ATE183085T1 (de) | 1999-08-15 |
DE69033775T2 (de) | 2001-11-15 |
ES2136686T3 (es) | 1999-12-01 |
ATE147626T1 (de) | 1997-02-15 |
WO1990015604A1 (en) | 1990-12-27 |
DK0737475T3 (da) | 2001-10-08 |
JP3165436B2 (ja) | 2001-05-14 |
ES2159661T3 (es) | 2001-10-16 |
EP0478694A4 (en) | 1992-07-29 |
JP2001081046A (ja) | 2001-03-27 |
DE69033246D1 (de) | 1999-09-16 |
HK1007681A1 (en) | 1999-04-23 |
EP0478694A1 (en) | 1992-04-08 |
DE69033775D1 (de) | 2001-09-06 |
DE69029734D1 (de) | 1997-02-27 |
US5356892A (en) | 1994-10-18 |
EP0478694B1 (en) | 1997-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6410544B1 (en) | Cholinergic agents in the treatment of presbyopia | |
US5122522A (en) | Treatment and control of ocular development | |
JP3165436B2 (ja) | 眼の発達の治療及び制御 | |
CN114306331B (zh) | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 | |
KR20230048067A (ko) | 근시 치료, 근시 예방 및/또는 근시 진행 억제를 위한 의약 | |
CA2160798C (en) | Gaba-ergic modulation of eye growth | |
US5360801A (en) | Pharmacological stimulation of eye growth | |
EP0556947A1 (en) | Use of M1-selective antimuscarinic pyridobenzodiazepinones for the treatment and prevention of axial myopia | |
EP0647445B1 (en) | Composition for prophylaxis and treatment of myopia | |
CA2369054C (en) | Treatment and control of ocular development | |
US5461052A (en) | Prevention of myopia by tricyclic compounds | |
US5320839A (en) | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use | |
WO1993006827A1 (en) | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070312 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070320 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070807 |